HZ-V055 / HealZen Therap - LARVOL DELTA

HZ-V055, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in RasMut cancer models (AACR 2026) - "In summary, HZ-V055 is an orally available, selective pan-Ras molecular glue inhibitor. In preclinical models, its enhanced selectivity for KrasG12C/D/V mutants over wild-type (wt) K/H/N-Ras confers two key advantages over RMC-6236: reduced Ras(WT) pathway inhibition in skin tissues and a significantly expanded therapeutic window. Collectively, these preclinical findings validate HZ-V055 as a highly promising candidate for further clinical development."

Late-breaking abstract • Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRAF • DUSP6 • KRAS